JOURNAL OF PHARMA INSIGHTS AND RESEARCH

REVIEW ARTICLE

Current Scenario and Prospective Directions of Nanomedicine

Ankit[1], Monika*[1], Pragi Arora[1], Varun Kumar[1]

[1] *Department of Pharmacy, Jagannath University, Bahadurgarh, Haryana, India*

Publication history: Received on 9th March; Revised on 18th March; Accepted on 21st March

Article DOI: 10.5281/zenodo.10945613

Abstract: Nanomedicine, a branch of nanotechnology, involves highly specialized medical interventions at the molecular scale for treating diseases or repairing damaged tissues like bone, muscle, or nerve. This emerging field has the potential to significantly impact medical science. Researchers have been exploring nanomedicine as a promising advancement in antimicrobial therapies, successfully targeting bacteria with suitable in vitro results. Nanoanalytical tools enable the characterization of surface and interface properties at the nanometer scale, providing access to various industrial and therapeutic economic domains. These tools enhance drug delivery, biocompatibility, and neuroprosthetics. Several countries have actively pursued research and development in nanomedicine, with major contributions from the United States, the European Union (particularly Germany), and Japan since the inception of this discipline. This is evident from the exponential growth in the number of published articles and patent applications since 2004. However, by 2012, China surpassed other nations, second only to the United States, in terms of the total research articles published on nanomedicine. This review article aims to provide a concise introduction to nanomedicine and the application of nanotechnology in this field.

Keywords: Nanotechnology; Nanomedicine; Nanoanalytical tools; Biocompatibility; Drug delivery.

1. Introduction

For many years, the scientific field of nanotechnology has captivated the world. Defining it can be challenging since it emerged concurrently from various disciplines. Essentially, nanotechnology or nanoscience involves the study, manipulation, and application of particles at the nano scale. The American physicist Richard Feynman is credited with pioneering nanotechnology through his 1959 lecture, "There's Plenty of Room at the Bottom: An Invitation to Enter a New Field of Physics," which explained how to manipulate and control atoms and molecules. Nanomedicine refers to the application of science and technology for disease diagnosis, treatment, and prevention to provide the best possible medical care [1]. Similar to nanotechnology, the term "nanomedicine" is ill-defined and constantly evolving due to its unique properties that lie at the boundary of the molecular and bulk regimes. When materials are reduced to the nanoscale size, their properties, such as surface area to volume ratio, electrical and optical characteristics, and surface reactivity, change significantly. For example, copper, which is opaque at larger scales, becomes transparent and shifts from yellow to blue-violet at the nanoscale [2]. The size of the nanoparticle significantly influences its likelihood of interacting with tissues and cells, as well as its potential for causing harm [3]. It is evident that the field of nanomedicine has been overhyped, and its undue emphasis on cancer therapy has led to unfulfilled promises. Nanoparticles (NPs) can be utilized for targeted drug delivery in specific areas to improve the solubility of poorly water-soluble drugs [4].

The advancements in nanotechnology and its applications in drugs and medicine have transformed the twentieth century. Nanotechnology involves manipulating individual atoms, molecules, or compounds into structures to create materials and technologies with unique properties. [5] One of the most intriguing ideas in nanomedical research is the creation of multifunctional nanoparticle (NP) complexes that can simultaneously deliver therapeutic and diagnostic agents to specific sites. Nanotechnology involves working from the top down, or shrinking massive structures to the smallest sizes [6]. Research in nanomedicine is progressing rapidly, aided by investment and public policy [7, 8]. Potential benefits of further research and development of nanomedicines include improved efficacy, bioavailability, dose-response, targeting capability, customization, and safety compared to traditional medications [9]. Nevertheless, despite these positive aspects, there is currently a lack of crucial information about the pharmacokinetics, pharmacodynamics, and toxicity of many nanomaterials.[10]

Nanomedicine, a relatively new field, has been under study since the 1990s, exploring the potential applications of nanotechnology in pharmacology, medical technology, and medicine. Advances in high-resolution microscopy throughout the 20th century, spanning biology, physics, and chemistry, paved the way for new disciplines such as molecular biology, microelectronics, biochemistry,

* Corresponding author: Monika

nanobiotechnology, and nanomedicine. [11] Nanomedicine focuses on understanding cellular structure and function, as well as intra- and intercellular processes, at the molecular level using engineered nanodevices and nanostructures. Key challenges in nanomedicine include addressing issues related to the toxicity and environmental impact of nanoscale materials, which are materials with structures on the scale of nanometers (billionths of a meter). Despite these challenges, nanomedicine holds promise for developing advanced drug delivery systems, innovative therapeutics, and in vivo imaging techniques, offering valuable research tools and clinically useful devices in the near future

2. Current applications of Nanomedicine

2.1. Nanoparticles for Drug Delivery

Nanoparticles have emerged as promising drug delivery systems due to their unique properties, such as high surface-to-volume ratio, tunable size, and the ability to encapsulate and deliver various therapeutic agents. These nanocarriers can improve drug solubility, bioavailability, and pharmacokinetics, as well as target specific tissues or cells. [12] Some examples include:

2.1.1 Liposomes: Lipid-based nanoparticles used for delivering drugs, genes, and imaging agents.

2.1.2 Polymeric nanoparticles: Biodegradable polymers like poly(lactic-co-glycolic acid) (PLGA) used for controlled and sustained drug release.

2.1.3 Dendrimers: Highly branched, monodisperse polymers for delivering drugs, genes, and imaging agents.

2.1.4 Inorganic nanoparticles: Gold, silver, and iron oxide nanoparticles used for drug delivery and photothermal therapy. [13]

2.2. Nanomaterials for Diagnostics and Imaging

Nanomaterials have unique optical, magnetic, and electronic properties that make them valuable for various diagnostic and imaging applications. Some examples include:

2.2.1 Quantum dots: Semiconductor nanocrystals with size-tunable optical properties for bioimaging and diagnostic assays.

2.2.2 Superparamagnetic iron oxide nanoparticles (SPIONs): Used as contrast agents for magnetic resonance imaging (MRI) and magnetic particle imaging (MPI).

2.2.3 Gold nanoparticles: Used for computed tomography (CT) imaging, photothermal therapy, and biosensing.

2.2.4 Carbon nanotubes: Used for biosensing, bioimaging, and drug delivery. [14, 15]

2.3. Nanodevices for Tissue Engineering and Regenerative Medicine

Nanomaterials and nanostructures can be engineered to mimic the natural extracellular matrix (ECM) and provide physical and biochemical cues for tissue regeneration. Some examples include:

2.3.1 Nanofiber scaffolds: Electrospun nanofibers made of biodegradable polymers for tissue engineering applications.

2.3.2 Nanocomposite hydrogels: Hydrogels incorporating nanoparticles or nanostructures for controlled drug release and tissue regeneration.

2.3.3 Nanopatterns: Nanoscale topographical features on biomaterial surfaces for guiding cell behavior and tissue organization.

2.3.4 Nanocarriers for gene delivery: Nanoparticles for delivering therapeutic genes to promote tissue repair and regeneration. [16]

2.4. Nanobiosensors and Nanodiagnostics

Nanomaterials have been used to develop highly sensitive and specific biosensors and diagnostic devices for various applications, such as disease detection, environmental monitoring, and food safety. Some examples include:

2.4.1 Nanobiosensors: Sensors that incorporate nanomaterials (e.g., carbon nanotubes, graphene, metal nanoparticles) for enhanced sensitivity and selectivity in detecting biomolecules.

2.4.2 Nanoarrays and nanochips: Nanomaterial-based arrays and chips for high-throughput analysis of biomolecules, like DNA, proteins, and small molecules.

2.4.3 Nanofluidic devices: Devices with nanoscale channels and chambers for precise manipulation and analysis of biological samples.

2.4.4 Nanodiagnostics: Integration of nanomaterials and nanodevices for point-of-care diagnostics, such as lab-on-a-chip systems and paper-based diagnostics. [17]

3. Emerging trends and technologies in nanomedicine

3.1. Targeted drug delivery systems

One of the most promising emerging trends in nanomedicine is the development of targeted drug delivery systems. These systems aim to deliver therapeutic agents specifically to the desired site of action, minimizing off-target effects and improving therapeutic efficacy. Nanocarriers can be functionalized with targeting ligands, such as antibodies, peptides, or small molecules, that recognize and bind to specific receptors or biomarkers expressed on the target cells or tissues. Additionally, stimuli-responsive nanocarriers are being developed that can release their cargo in response to specific environmental cues, such as changes in pH, temperature, or the presence of certain enzymes. These targeted and responsive delivery systems have the potential to revolutionize the treatment of various diseases, including cancer, inflammatory disorders, and neurological conditions [18]

3.2. Theranostics

Theranostics, a portmanteau of "therapy" and "diagnostics," is an emerging field that combines diagnostic and therapeutic capabilities into a single platform. Nanomaterials with unique optical, magnetic, or radiolabeling properties can be used for imaging and simultaneously delivering therapeutic agents to the target site. For example, nanoparticles can be engineered to serve as contrast agents for imaging modalities like magnetic resonance imaging (MRI) or positron emission tomography (PET), while also carrying drugs or genes for targeted therapy. This integrated approach enables real-time monitoring of drug delivery, treatment efficacy, and disease progression, leading to personalized and more effective treatments. Theranostic nanoplatforms have shown great potential in various applications, including cancer, cardiovascular diseases, and neurodegenerative disorders. [19]

3.3. Nanomaterials for cancer therapy

Nanomedicine has made significant strides in the development of novel therapeutic approaches for cancer treatment. Nanomaterials can be engineered to overcome the limitations of conventional chemotherapeutic agents, such as poor solubility, non-specific biodistribution, and severe side effects. For instance, nanoparticles can be loaded with anticancer drugs and coated with targeting ligands for enhanced tumor accumulation and cellular uptake. Additionally, nanoparticles can be designed for photothermal or photodynamic therapy, where they absorb light energy and convert it into heat or reactive oxygen species, respectively, to induce cancer cell death. Moreover, nanocarriers can be used for gene therapy or RNA interference (RNAi) applications, delivering therapeutic nucleic acids to modulate gene expression in cancer cells. These nanomaterial-based approaches have shown promising results in preclinical and clinical studies, offering new hope for more effective and personalized cancer treatments. [20]

3.4. Nanotoxicology and safety concerns

While nanomedicine holds immense potential, the unique properties of nanomaterials also raise concerns about their potential toxicity and safety. Nanotoxicology is an emerging field that studies the interactions between nanomaterials and biological systems, aiming to understand and mitigate any potential adverse effects. Factors such as size, shape, surface chemistry, and route of exposure can influence the toxicity and biodistribution of nanomaterials. Additionally, the long-term effects of nanoparticle accumulation in various organs and the potential for immune system activation or disruption of biological processes need to be thoroughly investigated. Comprehensive nanotoxicological studies, including in vitro and in vivo assessments, are crucial for ensuring the safe and responsible development of nanomedicines. Regulatory agencies are actively working to establish guidelines and frameworks for the evaluation and approval of nanomedicinal products, ensuring their safety and efficacy before reaching the market [21]

4. Regulatory and commercialization aspects

Peptides in cosmeceuticals are categorized into several groups based on their distinct properties and functions, each contributing uniquely to skincare formulations.

4.1. Regulatory landscape

The regulatory landscape for nanomedicines is complex and evolving as regulatory agencies strive to keep pace with the rapid advancements in this field. Many countries have established specific regulatory guidelines or frameworks to ensure the safety, efficacy, and quality of nanomedicinal products. For instance, the U.S. Food and Drug Administration (FDA) has issued guidance documents and recommendations for the evaluation of nanomaterials in drug products, medical devices, and cosmetics. Similarly, the European Medicines Agency (EMA) has developed specific guidelines for the evaluation of nanomedicines, addressing aspects such as characterization, toxicology, and quality control. However, the regulatory landscape remains fragmented across different regions, and harmonization efforts are underway to streamline the approval processes and facilitate global development and commercialization of nanomedicines. [22]

4.2. Intellectual property and patenting

Intellectual property (IP) protection is crucial for the successful commercialization of nanomedicines. Patents play a vital role in protecting the innovative aspects of nanomaterials, nanodevices, and nanomedicinal formulations, as well as the processes involved in their development and manufacture. However, patenting in the field of nanomedicine can be challenging due to the complex nature of nanomaterials and the potential overlap with existing technologies. Thorough prior art searches and careful claim drafting are essential to secure robust patent protection. Additionally, issues such as patent thickets, where multiple patents cover different aspects of a technology, can hinder innovation and commercialization efforts. Effective IP strategies, including licensing agreements and collaborative partnerships, are crucial for navigating the complex IP landscape in nanomedicine. [23]

4.3. Challenges in commercialization

While nanomedicines hold tremendous promise, their commercialization and scaling up for widespread clinical use face several challenges. One of the major hurdles is the transition from laboratory-scale synthesis to large-scale, cost-effective, and reproducible manufacturing processes. Ensuring consistent quality, stability, and performance of nanomaterials and nanoformulations at an industrial scale is a significant challenge. Additionally, the complex nature of nanomaterials and their interactions with biological systems can make it difficult to predict and control their behavior in vivo, potentially leading to regulatory hurdles and safety concerns. Furthermore, the high development costs and lengthy regulatory approval processes can pose financial barriers, particularly for small companies and academic institutions. Overcoming these challenges requires collaborative efforts between academia, industry, and regulatory authorities, as well as innovative approaches to manufacturing, quality control, and cost-effective production processes. [24]

The global nanomedicine market is expected to witness significant growth in the coming years, driven by the increasing prevalence of chronic diseases, advancements in nanotechnology, and the demand for personalized and targeted therapies. According to market research reports, the nanomedicine market is projected to reach billions of dollars by the end of the decade, with applications spanning various therapeutic areas, including oncology, cardiovascular diseases, neurodegenerative disorders, and infectious diseases. However, the market growth is influenced by factors such as regulatory approvals, reimbursement policies, and the successful translation of research into commercial products. Investment trends in nanomedicine reflect a growing interest from pharmaceutical companies, biotechnology firms, and venture capital investors, recognizing the potential of this emerging field. Collaborations between academia, industry, and government agencies are crucial for driving innovation, fostering entrepreneurship, and accelerating the commercialization of nanomedicinal products [25]

5. Future perspectives

Nanomedicine holds immense potential for revolutionizing healthcare and addressing some of the most pressing global health challenges. As research and development in this field continue to advance, several exciting prospects lie ahead:

5.1.1. Personalized Medicine

Nanomedicines can be tailored to individual patients' genetic profiles, disease characteristics, and therapeutic responses, enabling truly personalized and precision medicine approaches. [26]

5.1.2. Multi-Functional Nanoplatforms

The integration of multiple functionalities, such as imaging, therapy, and biosensing, into a single nanoplatform will lead to more effective and comprehensive disease management strategies.

5.1.3. Organ-on-a-Chip and Microphysiological Systems

The development of organ-on-a-chip and microphysiological systems incorporating nanomaterials and nanostructures will provide more realistic in vitro models for drug testing, disease modeling, and toxicology studies.[27]

5.1.4. Nanomedicine in Regenerative Medicine

The use of nanomaterials and nanostructures in tissue engineering and regenerative medicine will continue to advance, enabling the creation of biomimetic scaffolds and microenvironments for tissue repair and regeneration.

5.1.5. Nanotechnology-Enabled Wearable and Implantable Devices

The integration of nanomaterials and nanosensors into wearable and implantable devices will revolutionize continuous health monitoring, disease detection, and personalized treatment delivery.

5.1.6. Interdisciplinary Collaboration

Nanomedicine is inherently an interdisciplinary field, and fostering collaborations among researchers from various disciplines, such as materials science, biology, engineering, and medicine, will be crucial for driving innovation and translating discoveries into clinical applications [28]

6. Conclusion

Nanomedicine is a rapidly evolving and multidisciplinary field that holds tremendous promise for transforming healthcare and improving patient outcomes. While significant progress has been made in the development of nanomaterials, nanodevices, and nanomedicinal products, several challenges remain, including regulatory hurdles, scaling up and manufacturing issues, and potential safety concerns. Addressing these challenges will require concerted efforts from academia, industry, regulatory agencies, and policymakers. By leveraging the unique properties of nanomaterials and embracing interdisciplinary collaborations, nanomedicine has the potential to revolutionize disease diagnosis, treatment, and prevention, ultimately leading to more personalized, targeted, and effective healthcare solutions. As research and development in this field continue to advance, nanomedicine is poised to play a pivotal role in addressing global health challenges and improving the quality of life for millions of people worldwide.

References

[1] Bawa R, Bawa SR, Maebius SB, Flynn T, Wei C. Protecting new ideas and inventions in nanomedicine with patents. Nanomedicine. 2005;1(2):150-8.

[2] Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16-20.

[3] Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-82.

[4] Mannaa S, Lakshmia US, Racharlaa M, Sinhab P, Kanthala LK, Kumara SP. Bioadhesive HPMC gel containing gelatin nanoparticles for intravaginal delivery of tenofovir. Journal of Applied Pharmaceutical Science. 2016 Aug 30;6(8):022-9.

[5] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.

[6] Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4(128):128ra39.

[7] Muthu MS, Leong DT, Feng SS. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014;4(6):660-77.

[8] Tummala SR, Amgoth KP. Development of GC-MS/MS Method for Simultaneous Estimation of Four Nitrosoamine Genotoxic Impurities in Valsartan. Turkish Journal of Pharmaceutical Sciences. 2022 Aug;19(4):455

[9] Thakor AS, Gambhir SS. Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin. 2013;63(6):395-418.

[10] Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev. 2013;65(1):21-3.

[11] Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012;338(6109):903-10.

[12] Nel AE, Mädler L, Velegol D, Xia T, Hoek EM, Somasundaran P, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543-57.

[13] Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005;113(7):823-39.

[14] Boisseau P, Loubaton B. Nanomedicine, nanotechnology in medicine. C R Phys. 2011;12(7):620-36.

[15] Sarella PN, Vipparthi AK, Valluri S, Vegi S, Vendi VK. Nanorobotics: Pioneering Drug Delivery and Development in Pharmaceuticals. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024 Feb 22;16(1):81-90.

[16] Sozer N, Kokini JL. Nanotechnology and its applications in the food sector. Trends Biotechnol. 2009;27(2):82-9.

[17] Sekhon BS, Kamboj SR. Inorganic nanomedicine-part 1. Nanomedicine. 2010;6(2):516-22.

[18] Shao K, Singha S, Clemente-Casares X, Tsai S, Yang Y, Santamaria P. Nanoparticle-based immunomodulatory therapies against autoimmune diseases. Trends Immunol. 2015;36(7):416-26.

[19] Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3):311-30.

[20] Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001;219(2):316-33.

[21] Ding Y, Jiang Z, Saha K, Kim CS, Kim ST, Landis RF, et al. Gold nanoparticles for nucleic acid delivery. Mol Ther. 2014;22(6):1075-83.

[22] Tasciotti E, Liu X, Bhavane R, Plant K, Leonard AD, Price BK, et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol. 2008;3(3):151-7.

[23] Chen PC, Mwakwari SC, Oyelere AK. Gold nanoparticles: From nanomedicine to nanosensing. Nanotechnol Sci Appl. 2008;1:45-66.

[24] Doane TL, Burda C. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem Soc Rev. 2012;41(7):2885-911.

[25] Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161-71.

[26] Patra JK, Das G, Fraceto LF, Campos EV, Rodriguez-Torres MD, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.

[27] Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.

[28] Sarella PN, Thammana PK. Potential applications of Folate-conjugated Chitosan Nanoparticles for Targeted delivery of Anticancer drugs. Research Journal of Pharmaceutical Dosage Forms and Technology. 2023 Oct 1;15(4):281-8.